IPO Listed — 29 May 2026
Listing Price: ₹111.20
Bio Medica Laboratories SME IPO GMP History | Listing Price ₹111.20 & Kostak Rate
Bio Medica Laboratories SME IPO has been listed on May 29, 2026 at a listing price of ₹111.20, against the issue price of ₹139 — a loss of ₹27.8 (-20%). The GMP peaked at ₹4 on 22 May 2026 and reached a low of ₹0 on 25 May 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Bio Medica Laboratories SME IPO raised ₹52 Cr. through its IPO at a price band of ₹132 to ₹139 per share, with a lot size of 1000 shares. The IPO was open for subscription from 21 May 2026 to 25 May 2026.
Table of Contents
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 27 May 2026 | ₹ 2 | 1% | ₹ 0 | ₹ 0 | |
| 26 May 2026 | ₹ 2 | 1% | ₹ 0 | ₹ 0 | |
| 25 May 2026 | ₹ 0 | -- | ₹ 0 | ₹ 0 | |
| 23 May 2026 | ₹ 2 | 1% | ₹ 0 | ₹ 0 | |
| 22 May 2026 | ₹ 4 | 3% | ₹ 0 | ₹ 0 | |
| 21 May 2026 | ₹ 0 | -- | ₹ 0 | ₹ 0 | |
| 20 May 2026 | ₹ 0 | -- | ₹ 0 | ₹ 0 | |
| 19 May 2026 | ₹ 0 | -- | ₹ 0 | ₹ 0 | |
| 18 May 2026 | ₹ 0 | -- | ₹ 0 | ₹ 0 |
Bio Medica Laboratories SME IPO Dates
| Event | Date |
|---|---|
| Open Date | 21 May, 2026 |
| Close Date | 25 May, 2026 |
| Allotment Date | 26 May, 2026 |
| Refund Date | 27 May, 2026 |
| Credit to Demat | 27 May, 2026 |
| Listing Date | 29 May, 2026 |
Bio Medica Laboratories SME IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹139 |
| GMP-Based Estimate (Pre-Listing) | ₹141 (+1.4%) |
| Actual Listing Price | ₹111.20 (-20%) |
| Listing Gain / Loss | ₹-27.8 per share |
| Listing Date | 29 May, 2026 |
Is Bio Medica Laboratories SME IPO GMP Reliable?
Grey market premium for Bio Medica Laboratories SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Bio Medica Laboratories SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Bio Medica Laboratories SME IPO IPO Kostak Rate Explained
The Kostak rate for Bio Medica Laboratories SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Bio Medica Laboratories SME IPO
The company operates on a business model centred around the development, production, and distribution of pharmaceutical formulations and healthcare solutions across multiple therapeutic segments. Its product offerings include tablets, capsules, syrups, injections, and other medical formulations supplied through distributors and healthcare networks. The business is promoted by experienced industry professionals who focus on expanding market reach, improving manufacturing capabilities, and strengthening the company’s position in the domestic pharmaceutical industry.
Strengths & Risks
Strengths
- ✓ Experienced promoters and management team with pharma industry knowledge.
- ✓ Diversified portfolio of injectable pharmaceutical products for human and veterinary use.
- ✓ Strong quality assurance systems supported by GMP-certified manufacturing facilities.
- ✓ Established relationships with clients across multiple Indian states and healthcare markets.
- ✓ Significant improvement in revenue, EBITDA margins, and profitability during recent financial years.
Risks
- ⚠ High dependence on key customers may impact revenue if orders decline.
- ⚠ Any quality control failure could damage reputation and invite legal liabilities.
- ⚠ Failure to adopt new pharmaceutical technologies may affect future competitiveness.
- ⚠ Negative cash flow risks may create pressure on expansion and working capital needs.
- ⚠ The company operates from premises that are not fully owned, creating operational dependency risks.
Frequently Asked Questions about Bio Medica Laboratories SME IPO
What is the GMP of Bio Medica Laboratories SME IPO?
The current Grey Market Premium (GMP) of Bio Medica Laboratories SME IPO is ₹ 2.
What is the Kostak Price of Bio Medica Laboratories SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Bio Medica Laboratories SME IPO is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What is the Subject to Sauda Price of Bio Medica Laboratories SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What was the actual listing price of Bio Medica Laboratories SME IPO?
Bio Medica Laboratories SME IPO listed on May 29, 2026 at ₹111.20, against the issue price of ₹139 — a loss of -20%.
How did the GMP of Bio Medica Laboratories SME IPO trend before listing?
The GMP of Bio Medica Laboratories SME IPO was stable in its final days before listing. The GMP peaked at ₹4 on 22 May 2026. View the day-wise table above for the complete GMP history.
Explore Bio Medica Laboratories SME IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!